Targeting microRNA-122 to Treat Hepatitis C Virus Infection
Author Information
Author(s): Catherine L. Jopling
Primary Institution: School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham
Hypothesis
Can targeting microRNA-122 provide an effective treatment for Hepatitis C Virus (HCV) infection?
Conclusion
Inhibiting microRNA-122 in chimpanzees with chronic HCV infection led to a sustained reduction in viral load.
Supporting Evidence
- Three out of four treated chimpanzees showed a sustained reduction in viral load.
- The reduction in HCV RNA was gradual and lost once the inhibitor was withdrawn.
- No adaptive mutations were detected in the miR-122 binding region of HCV RNA during treatment.
Takeaway
Scientists are trying to use a tiny molecule called microRNA-122 to help fight a virus that makes people sick. When they blocked this molecule in some monkeys, the virus got weaker.
Methodology
The study involved administering an LNA-antimiR-122 inhibitor to chimpanzees infected with HCV and monitoring the effects on viral load.
Limitations
The study was conducted on a small number of chimpanzees, making it difficult to draw broad conclusions.
Participant Demographics
Chimpanzees chronically infected with HCV.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website